Lumida
/PRCT
⌘K
Procept Biorobotics Corp

Procept Biorobotics Corp

PRCT
$20.38USD+1.54%+0.31 today

MARKET CAP

1.2B

P/E (TTM)

FWD P/E

DAY RANGE

$20 – $21

52W RANGE

$17
$40

AI Summary

Stalk
TrimMedium

Given the ongoing Stage 4 downtrend with price below key SMAs and lower highs persisting, the medium-term bias remains bearish. However, bearish exhaustion signals suggest near-term seller fatigue and potential short-term bounces. Under the speculative strategy, trimming into rallies around the 9/20/50 EMAs at prior support-turned-resistance areas is the preferred approach. A lack of decisive reversal above intermediate structure maintains bearish bias while deferring execution to favorable retracements.

  • Q1 revenue up 20.1% YoY; Q2 2026 guidance at $92.6M confirms growth
  • Robotic BPH system adoption rising, offering precision advantage over alternatives
  • Projected Q2 2026 loss of $0.46 per share highlights ongoing unprofitability
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$34.5M$75.0M$136.2M$224.5M$308.1M
YoY %+117.6%+81.6%+64.8%+37.2%
P / Sales12.0x23.4x14.4x18.7x5.7x
EV / Sales5.2x22.0x13.4x17.8x5.2x
Gross Profit, Adj.$15.9M$37.1M$71.0M$137.1M$196.2M
YoY %+133.8%+91.6%+93.0%+43.1%
Margin %46.0%49.4%52.2%61.1%63.7%
EV / Gross Profit11.2x44.4x25.7x29.1x8.2x
EBITDA, Adj.$-50.8M$-77.9M$-105.4M$-91.4M$-97.5M
YoY %-53.2%-35.3%+13.3%-6.7%
Margin %-147.5%-103.8%-77.4%-40.7%-31.6%
EV / EBITDA-3.5x-21.1x-17.3x-43.7x-16.4x
EBIT$-54.2M$-80.7M$-109.2M$-96.6M$-103.9M
YoY %-49.0%-35.2%+11.5%-7.5%
Margin %-157.1%-107.6%-80.2%-43.0%-33.7%
EV / EBIT-3.3x-20.4x-16.7x-41.4x-15.4x
Net Income$-59.9M$-87.2M$-105.9M$-91.4M$-95.6M
YoY %-45.6%-21.5%+13.7%-4.5%
Net Margin-173.6%-116.2%-77.8%-40.7%-31.0%
EPS (GAAP)-$3.63-$1.96-$2.24-$1.75-$1.72
YoY %+46.0%-14.3%+21.9%+1.7%